WEE1 and plasma cell myeloma: Moreover, this CK2 inhibitor is able to be internalised in resistant cells with a subsequent ability to induce cell death.65 CK2 is a protein kinase whose role in tumorigenesis is well established66 and for this reason the drug CX-4945 is currently in further cancer clinical trials, including in combination with chemotherapy for its use against cholangiocarcinoma (ClinicalTrials.Gov Identifier: NCT02128282) and also for the treatment of multiple myeloma (ClinicalTrials.Gov Identifier: NCT01199718).